Clicky

AbbVie Inc(4AB)

Description: AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.


Keywords: Pharmaceutical Drugs Organic Compounds Chemical Compounds Infection Parkinson's Disease Anemia Migraine Breakthrough Therapy Constipation Irritable Bowel Syndrome Chronic Lymphocytic Leukemia Eye Care Products Endometriosis Hypothyroidism Ocular Hypertension Tyrosine Kinase Inhibitors Uterine Fibroid Levodopa Advanced Prostate Cancer Combination Drugs Carbidopa Exocrine Pancreatic Insufficiency Genotype Severe Plaque Psoriasis Botox Humira Open Angle Glaucoma Chronic Idiopathic Constipation Severe Active Rheumatoid Arthritis Central Precocious Puberty Ibrutinib Lupron

Home Page: www.abbvie.com

1 North Waukegan Road
North Chicago, IL 60064-6400
United States
Phone: 847 932 7900


Officers

Name Title
Mr. Richard A. Gonzalez Chairman & CEO
Mr. Robert A. Michael Vice Chairman & Pres
Ms. Laura J. Schumacher Vice Chairman of External Affairs & Chief Legal Officer
Mr. Jeffrey Ryan Stewart Exec. VP & Chief Commercial Officer
Mr. Scott T. Reents Exec. VP & CFO
Dr. Azita Saleki-Gerhardt Ph.D. Exec. VP of Operations
Dr. Thomas J. Hudson Sr. VP of R&D and Chief Scientific Officer
Ms. Elizabeth Shea VP of Investor Relations
Mr. Perry C. Siatis Exec. VP, Gen. Counsel & Sec.
Mr. Timothy J. Richmond Exec. VP & Chief HR Officer

Exchange: F

Country: DE : Germany

Currency: Euro (€)

Forward PE: 14.2653
Trailing PE: 20.5092
Price-to-Book MRQ: 18.0664
Price-to-Sales TTM: 4.7246
IPO Date:
Fiscal Year End: December
Full Time Employees: 50000
Back to stocks